HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.
Expert Rev Vaccines
; 19(1): 71-84, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31957513
ABSTRACT
Introduction:
Although successful at suppressing HIV replication, combination antiretroviral therapy (cART) only partially restores immune functions and fails to reduce the latent HIV reservoir, thus requiring novel interventions for its intensification.Areas covered Here are reviewed therapeutic vaccine candidates that are being developed to this goal. Among them, the Tat vaccine has been shown to promote immune restoration, including CD4+ T-cell recovery in low immunological responders, and to reduce the virus reservoirs well beyond what achieved with long-term suppressive cART.Expert opinion The authors propose the Tat vaccine as a promising vaccine candidate for cART intensification toward HIV reservoirs depletion, functional cure, and eradication strategies, suggesting that targeting a key protein in the virus life cycle is pivotal to success.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Vacinas contra a AIDS
/
Fármacos Anti-HIV
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article